Patients with advanced breast cancer often fail to respond to treatment, creating a need to develop novel biomarkers and effective therapeutics. Dopamine (DA) is a catecholamine that binds to five G protein-coupled receptors. We discovered expression of DA type-1 receptors (D1Rs) in breast cancer, thereby identifying these receptors as novel therapeutic targets in this disease. Strong to moderate immunoreactive D1R expression was found in 30% of 751 primary breast carcinomas, and was associated with larger tumors, higher tumor grades, node metastasis and shorter patient survival. DA and D1R agonists, signaling through the cGMP/ protein kinase G (PKG) pathway, suppressed cell viability, inhibited invasion and induced apoptosis in multiple breast cancer cell lines. Fenoldopam, a peripheral D1R agonist that does not penetrate the brain, dramatically suppressed tumor growth in two mouse models with D1R-expressing xenografts by increasing both necrosis and apoptosis. D1R-expressing primary tumors and metastases in mice were detected by fluorescence imaging. In conclusion, D1R overexpression is associated with advanced breast cancer and poor prognosis. Activation of the D1R/cGMP/PKG pathway induces apoptosis in vitro and causes tumor shrinkage in vivo. Fenoldopam, which is FDA (Food and Drug Administration) approved to treat renal hypertension, could be repurposed as a novel therapeutic agent for patients with D1R-expressing tumors.
INTRODUCTION Dopamine (DA) is a catecholamine that acts as a major neurotransmitter in the brain and as a circulating hormone in the periphery, where it is produced by sympathetic nerves, adrenal medulla and gastrointestinal tract. 1 DA receptors (DARs) are expressed in kidney, gut and coronary arteries, 1, 2 and their dysregulation is associated with hypertension, gut motility disorders and metabolic dysfunctions. [2] [3] [4] After discovering expression of functional DAR in human adipocytes and breast adipose tissue, 5 we questioned whether they are also expressed in breast cancer, and if so, what are their functions.
DA binds to five G protein-coupled membrane receptors (GPCRs), grouped by structure, pharmacology and function into DA type-1 receptor (D1R)-like (D1R and D5R) and D2R-like (D2R, D3R and D4R) receptors. According to the original classification, D1R-like receptors are coupled to Gαs proteins, activate adenylate cyclase (AC), increase cAMP and stimulate protein kinase A (PKA), while D2R-like receptors are coupled to Gαi/o proteins, inhibit AC, suppress cAMP and inhibit PKA. 6 Such classification is oversimplified, however, since DAR can couple to other G proteins and activate alternative signaling pathways such as the guanylate cyclase (GC)/cGMP/protein kinase G (PKG) pathway. 7, 8 Activation of D1R-like in striatal neurons, 9,10 coronary arteries 11 and adipocytes 5 increases cGMP, which is generated from GTP by two GCs: particulate (pGC) and soluble (sGC). The pGCs are activated by natriuretic peptides, while cytosolic sGCs are the main targets of nitric oxide (NO); 12 sGC can be directly stimulated by YC-1 and Riociguat. 13 Elevated cAMP or cGMP is rapidly hydrolyzed by phosphodiesterases (PDEs), a superfamily with 11 members that differ in substrate specificity and catalytic properties.
14 Viagra (Sildenafil), Cialis (Tadalafil) and Levitra (Vardenafil), used to treat erectile dysfunction, selectively inhibit PDE5 that hydrolyzes cGMP, 15 resulting in sustained cGMP elevation that can lead to apoptosis. 16 Cialis has the longest half-life of the PDE5 inhibitors. 17 Dopaminergic drugs are widely used to treat Parkinson's disease, schizophrenia, addiction and hyperprolactinemia. Fenoldopam (Fen) is a high affinity (Kd = 2.3 nM) peripheral D1R agonist, 18 which does not activate D2R and does not penetrate the brain. Fen is FDA (Food and Drug Administration) approved to treat renal hypertension, 19 while causing only a small drop in blood pressure in normotensive patients. 20 Given its short half-life in the circulation, 21 Fen is commonly administered by infusion. Our objectives were to (1) explore D1R expression in breast cancer cell lines and primary carcinomas, and examine for correlations with tumor attributes and disease outcome; (2) determine whether D1R activation induces apoptosis in breast cancer cells, and investigate the mechanism involved; (3) examine whether Fen suppresses tumor growth in mouse xenograft models; and (4) develop an imaging approach for visualizing D1R-expressing tumors and metastases.
RESULTS

D1R expression in breast carcinomas and cell lines
The DRD1 transcript, cloned from MDA-MB-231 cells, was found identical to the published sequence. Breast carcinomas and matched normal breast tissue from the same individuals were analyzed for DRD1 gene expression by RT-PCR (Figure 1a) , and D1R proteins by western blotting (Figure 1b) . DRD1 expression was higher in tumors than in normal breast in 4/7 samples, while tumor D1R proteins were higher in 6/7 samples. Expression of D1R and D2R proteins was compared in eight breast cancer cell lines (Figure 1c ). D1R proteins were most abundant in the triplenegative MDA-MB-231, SUM159 and MDA-MB-468 cells, and generally lower in the estrogen receptor (ER)-positive MCF7, T47D and BT474 cells, except for the ER-positive MDA-MB-175 cells. All cell lines also expressed variable levels of D2R (Figure 1c) .
Given reports on lack of specificity of some antibodies against DAR, 22, 23 we validated the rabbit anti-D1R monoclonal antibodies (mAb) used here. Antibody pre-absorption with the immunizing peptide abolished the D1R bands in cell lysates (Figure 1d ). DRD1 knockdown by short hairpin RNA (shRNA) in MDA-MB-231 cells ( Figure 1e ) and HEK293T cells (Figure 1f ) markedly decreased the D1R protein band (Figures 1g and h, respectively) ; D1R knockdown did not affect D2R protein levels in MDA-MB-231 cells (Figure 1g ). Fen did not suppress the viability of MDA-MB-231 cells with downregulated D1R (Figure 1i ).
Immunohistochemistry (IHC) was used to visualize D1R in carcinomas and normal breast tissue. Figure 2a shows a carcinoma with strong D1R staining, which was eliminated by antibody preabsorption with immunizing peptide (Figure 2b) . A D1R-negative carcinoma and D1R-negative normal breast tissue are shown in Figures 2c and d (Figure 2e ), while 56% of tumors and all normal breast tissue samples were D1R negative. D1R staining was significantly associated with pre-menopausal age, ER-negative, progesterone receptor (PR)-negative, but Her2-overexpressing tumors (Table 2) . A significant association was seen between D1R-positive tumors and higher tumor stage (Figure 2f ), grade ( Figure 2g ) and node metastases ( Figure 2h) . A Kaplan-Meier analysis of 508 tumors revealed that patients with D1R-negative tumors had a median survival of 12 years, compared with 6 years for those with D1R-positive tumors ( Figure 2i) ; recurrence-free survival was similarly shortened (Figure 2j ). Supplementary Table 3 shows the statistical analyses. (Fen) . Cells stably transfected with scrambled or DRD1 shRNA sequences were incubated with Fen for 4 days and cell viability was analyzed by resazurin (means ± s.e.m., n = 6, *P o0.05). Gel images and graphs in this and subsequent figures are representative of at least three experiments.
Suppression of cell viability and induction of apoptosis DA and three D1R agonists markedly suppressed viability of MDA-MB-231 and MDA-MB-468 cells, whereas cabergoline, a D2R agonist, had no effect (Figure 3a ). DA and Fen caused a 25-50% suppression of BT-20 and SUM159 viability, were less effective in T47D cells and were ineffective in MCF7 cells (Figure 3b) .
Reduced cell viability could be due to decreased proliferation and/or increased apoptosis. Since bromodeoxyuridine (BrdU) incorporation was unaltered by D1R activation (Figure 4d We reasoned that if D1R activation reduces cell viability by increasing cGMP, bypassing the receptor and directly stimulating cGMP should have similar effects. Indeed, Figure 6b shows that YC-1, a direct sGC stimulator, reduced cell viability to 5-25% of controls, whereas KT5823, a selective PKG inhibitor, prevented Fen-induced apoptosis (Figure 6c ), confirming mediation of apoptosis by PKG. Cialis, which blocks PDE5 and prolongs cGMP elevation, moderately suppressed cell viability when used alone, but markedly enhanced Fen-induced apoptosis to 15% of controls ( Figure 6d ). Other signaling pathways, for example, ERK1/2, Akt and CREB, were differentially activated by Fen (Supplementary Figure S1 ). To verify that DA inhibits cell viability via D1R, cells were pretreated with the D1R antagonist SCH39166. 
In vivo imaging of D1R-expressing tumors
We also developed in vivo imaging for detecting D1R-expressing tumors. Mice with MDA-MB-231-derived tumors were intravenously injected with rabbit anti-D1R mAb conjugated to AlexaFluor 647 fluorescent dye. Figure 7c shows fluorescence imaging 24 h after the injection. One mouse shows intense fluorescence at the primary tumor, while another also has fluorescence in distal metastases, as confirmed histologically (Figure 7c ). These data suggest that D1R is a novel prognostic biomarker in advanced breast cancer. D1R expression can be detected in tumor biopsies by IHC, or by non-invasive imaging such as positron emission tomography, using radioactive D1R-selective ligands. 25, 26 We foresee that many patients could benefit from targeted D1R therapy. FDA-approved drugs such as Fenoldopam, Riociguat, a sGC activator, 27 and Cialis, a PDE5 inhibitor, could be repurposed for treating breast cancer patients with advanced disease who do not respond to standard treatments.
Expression of DAR in peripheral tissues and in some cancers has been reported, 2 but there is only scant information on their expression in breast cancer. A small study reported binding of [H 3 ] spiperone, a D2R-like antagonist, in breast tumors, 28 and a recent study described D3R and D5R expression in breast cancer stem cells. 29 However, there are no reports on specific detection of D1R expression in human tumors outside the brain. Nonetheless, an epidemiological study found an association between DAR antagonists (that is, antipsychotics and anti-emetics) and a small increase in breast cancer risk. 30 DA and three D1R agonists suppressed cell viability, inhibited invasion and induced apoptosis in multiple breast cancer cell lines, while a D2R agonist was ineffective. Others reported that DA or its agonists induce apoptosis in neuroblastoma, 31 leukemia, 29 ovarian, 32 breast 29,33,34 and colon 33 cancer cells. However, most studies did not identify which DAR was expressed in their samples, and often used DA or its agonists at high pharmacological doses, raising the possibility of toxic effects. In contrast, we have confirmed expression of both D1R gene and protein in breast cancer cell lines and primary carcinomas, and demonstrated that selective D1R agonists at low nM doses suppress cell viability and induce apoptosis. Because DRD1 has no introns, our studies carefully verified lack of genomic DNA contamination and we also validated the specificity of the anti-D1R antibodies.
It appears counterintuitive that increased D1R expression correlates with advanced disease while D1R activation, rather than its suppression, results in apoptosis. This enigma raises several questions: (a) Is the DRD1 gene coincidentally upregulated in tumors because of proximity to an overexpressed oncogene in One group (HF) had the pumps for 3 weeks, while another (HF:7D), had the pumps removed after 1 week (means ± s.e.m., n = 6-8 mice). All time points in the two groups were lower than controls (P o0.05). (h) SUM159-derived tumor weights 3 weeks after Alzet implantation (*P o0.05).
breast carcinomas?, (b) Does D1R have ligand-independent actions as is the case for Her-2?, (c) Does D1R heterodimerize with another DAR or with other GPCRs?, 35 (d) Is the functional link between D1R and the cGMP apoptotic pathway being maintained or is lost during tumor progression?, (e) What is the minimal level of D1R expression which is necessary for responsiveness to a ligand? and (f) Does D1R have a different role during initiation, progression and/or metastatic stages of the disease? These questions should be addressed in future investigations.
Another issue is whether circulating DA alters growth of DARexpressing tumors. Free DA circulates at very low levels, well below its Kd values. However, most DA in humans circulates as DA-sulfate (DA-S), at 10-fold higher basal serum levels than all free catecholamines combined. 36 Sulfo-conjugation of DA, which is done in the gut by SULT1A3, is the major form of peripheral DA inactivation in humans, while glucuronidation predominates in rodents. 37 DA-S does not bind DAR and is biologically inactive. However, unlike irreversible DA inactivation by deamination, O-methylation or glucuronidation, sulfoconjugation is reversed by arylsulfatase A, a releasable lysosomal enzyme. 38 Based on our discovery that human adipocytes express arylsulfatase A which converts DA-S to bioactive DA, 5 we postulate that DAR-expressing breast tumors respond to serum DA-S only if they have an active arylsulfatase A. Moreover, stimulation vs inhibition of tumor growth by circulating DA-S/DA depends on a balance of D1R-like and D2R-like expression in each tumor. Because Fen at low nM levels is highly selective for D1R, its ability to suppress D1R-expressing tumors should not be compromised by the presence of D2R-like. Notably, rodents do not have a SULT1A3 ortholog, 39 and have very low serum-free DA levels and no DA-S. Consequently, mice carrying human cancer xenografts are not good models for assessing whether serum DA-S/DA affects tumor growth in humans. Also, a proper response to agonists requires not only functional D1R, but also a coordinated action of all the components of the cGMP pathway (sGC, cGMP, PDE5 and PKG), which may differ among cell lines.
Our data show that D1R in breast cancer cells signals via the cGMP/PKG pathway, as reported for striatal neurons 9,10 and adipocytes. 5 Although D1R is classified by their ability to increase cAMP, we found a decrease, rather than an increase, in cAMP levels following D1R activation. This decrease may be secondary to elevated cGMP, which activates cAMP-hydrolyzing PDEs, underlying reciprocal relationships between the two cyclic nucleotides. 40 Striatal DA can signal through D1R to increase NO synthesis from L-arginine by activating neuronal NO synthase. 41, 42 Elevated NO levels lead to sGC activation, increased cGMP accumulation and PKG activation, which often result in apoptosis. 43 Future studies should examine the mode of coupling of D1R to sGC, and determine whether NO is an upstream component of the D1R/sGC/cGMP/PKG signaling pathway in breast cancer.
A combination of apoptosis and necrosis is likely responsible for the more robust effects of Fen in vivo than in vitro. Tumor necrosis could be due to activation of multiple pathways within tumor cells, some of which can suppress angiogenesis. 44 DA has been reported to inhibit angiogenesis in vivo by acting via D2R 32, 45, 46 by inhibiting vascular endothelial growth factor 47 and its receptor. 48 However, there is no evidence that Fen at the low nM levels used in this study binds to D2R and directly affects angiogenesis. The long-lasting effects of Fen after termination of infusion, together with a future development of slow release formulation of orallydeliverable Fen, bode well for its prospective benefits in the treatment of patients with D1R-expressing tumors. For all experiments, cells were plated in growth medium, followed by starvation in treatment medium containing 5% charcoal-stripped serum (Atlanta Biologicals) and 1 mM ascorbic acid (Sigma). After 24 h, cells were treated as indicated.
MATERIALS AND METHODS
DRD1 cloning from breast cancer cell lines
Total RNA was isolated using RNAspin isolation kit (GE Healthcare, Pittsburgh, PA, USA). Oligo dT-primed cDNA was synthesized using SuperScript II (Invitrogen, Carlsbad, CA, USA). A subset of the DRD1 transcript sequence, spanning a portion of the 5' UTR, the entire protein coding sequence and a portion of the 3' UTR (nucleotides 434-2316 of GenBank RefSeq NM_000794; Supplementary Table 1) was PCR amplified, using high fidelity Phusion DNA polymerase (Thermo Fisher Scientific, Pittsburgh, PA, USA) and cloned. DRD1 sequences were successfully isolated from MDA-MB-231, MDA-MB-468 and MCF-7 cell lines, and sequenced by Genewiz (South Plainfield, NJ, USA). The MDA-MB-231 sequence was confirmed by a complete sequencing of both strands and shared 100% identity with the published sequence.
Conventional RT-PCR and quantitative real-time PCR cDNA was synthesized from total RNA, using RT 2 HT First Strand Kit (Qiagen, Germantown, MD, USA). Because DRD1 does not contain introns, DNase was added during RNA isolation and cDNA synthesis, and samples were evaluated for genomic DNA contamination by omitting reverse transcriptase. PCR amplification was done with primers for DRD1, or with intron-spanning primers for β2-Microglobulin (Supplementary Table 1 ). For conventional RT-PCR, products were resolved on 1.5% agarose gel and photographed. Quantitative real-time PCR (qPCR) was done using SYBR Green, and products were detected with a StepOnePlus instrument (Applied Biosystems, Carlsbad, CA, USA). Product purity was verified using DNA melting curve analysis and agarose gel electrophoresis. PCR efficiency was determined by the LinRegPCR program. Fold changes in Figure 8 . Proposed model of D1R signaling via the cGMP/PKG pathway in breast cancer cells. Fen binds to D1R, activates sGC, increases cGMP levels and activates PKG. This culminates in increased apoptosis and decreased invasion. This pathway can also be activated by YC-1 through sGC, and by Cialis, through a blockade of PDE5. SCH39166 is a selective D1R antagonist while KT5823 is a selective PKG antagonist. Inducible nitric oxide synthase (iNOS) may mediate the activation of sGC by D1R. FDA-approved drugs for various diseases are underlined.
gene expression were calculated from cycle threshold and efficiency measurements.
Western blot analysis
Cells and tissue lysates (40 μg/sample) were separated on 12% SDS gels and transferred onto PDVF membranes. After overnight incubation with primary antibodies (Supplementary Table 2 ), followed by horseradish peroxidase-conjugated secondary antibodies, products were exposed to SuperSignal chemiluminescence reagents (Pierce, Rockford, IL, USA) and photographed. β-Actin was a loading control. For antibody validation, the rabbit anti-D1R mAb was incubated for 10 min with the immunizing peptide, matching the human D1R C-terminus sequence (Novus, NBP1-79050PEP, Novus, Littleton, CO, USA), before incubation with blots.
Knockdown of DRD1 expression A shRNA vector against human DRD1 (MISSION shRNA SHCLND-NM_000794; TRCN0000011334, Sigma) was used to knockdown DRD1 gene expression; scrambled vector (Sigma) was a negative control. Cells were transfected using Lipofectamine 2000 (Invitrogen). Knockdown was confirmed by qPCR and western blotting. For stable transfections, cells were selected using 0.5 μg/ml puromycin (Invivogen), and positive colonies were expanded.
Tissue samples
Matched frozen tissue or formalin-fixed paraffin-embedded (FFPE) slides of breast carcinomas and normal breast tissues were obtained from the University of Cincinnati Pathology Department. The institutional review board approved the use of de-identified samples; informed consent was obtained from all patients. TMAs containing FFPE samples of breast carcinomas and normal breast tissues were purchased from Lifespan Biosciences (Seattle, WA, USA, LS-SBRCA121, n = 60), Biochain (Newark, CA, USA, Z7020005, n = 63; Z7020008, n = 53), Protein Biotechnologies (Ramona, CA, USA, TMA-1007, n = 67), NCI Cancer Diagnosis Program (CDP) (stage II (n = 340) or III (n = 168) prognostic TMAs). A total of 751 primary ductal carcinomas and 30 normal breast tissues were analyzed for D1R expression by IHC. Samples with known outcome (508) were used for Kaplan-Meier analysis of overall patient survival and recurrence-free survival.
Immunohistochemistry
Antigen retrieval was done in boiling sodium citrate buffer for 12 min. Non-specific antibody binding was blocked, and slides were incubated with anti-D1R mAb (1:500), followed by anti-rabbit horseradish peroxidaseconjugated secondary antibody (1:500). Diaminobenzidine (DAB) was the chromogen, with hematoxylin counter-staining. IHC statistics H-score results were averaged between duplicate samples and the two observers. ANOVA was performed for comparing H-score with tumor stage, grade and node metastases. P-values o0.05 were considered as significant, and those with significance were adjusted by the Bonferroni method. Data were divided into positive (H-score 450) and negative (H-score ⩽ 50) staining groups, and Pearson's chi-square analysis was used to test for independence across different tumor characteristics. A multivariate Cox proportional hazards model was used for predictors of mortality. Kaplan-Meier analysis was used for association between D1R-positive or D1R-negative tumors and patient survival and recurrence-free survival. All statistical analyses were done using JMP version 10 (SAS Institute, Cary, NC, USA).
Scoring of IHC
Cell viability assay
Cells plated at 5000 cells/well in 96-well plates were treated with DA, YC-1 (Sigma), Fen, SKF 38393, A68930, cabergoline (all from Tocris, Minneapolis, MN, USA), KT5823 (Cayman Chemical, Ann Arbor, MI, USA) or Cialis (Selleckchem, Houston, TX, USA). After 4 days, cell viability was determined by the resazurin fluorescence assay (Sigma).
Invasion assay
Cells were plated at 50 000 cells/well in serum-free medium on BioCoat Matrigel-coated inserts with 8 μm pore membranes (BD Biosciences, San Jose, CA, USA). Inserts were suspended over wells containing serumfree medium (Control), or medium with 10% FBS as chemoattractant with and without DA or Fen. After 24 h, non-invading cells were removed, and invading cells were stained with Hoechst fluorescent dye and Photographed at × 10 magnification (Zeiss Axioplan Imaging 2 microscope, Zeiss, Thornwood, NY, USA), and cell number per field was counted in a blinded manner. Experiments included three inserts per treatment, with six random fields photographed per insert.
Flow cytometry
Cells plated at 200 000 cells/well in 6-well plates were treated for 48 h with drugs. Apoptosis was determined using FITC Annexin V Apoptosis Detection Kit 1 (556547; BD Pharmingen), and analyzed by flow cytometry using a Cell Lab Quanta SC Flow Cytometer (Beckman Coulter, Indianapolis, IN, USA). About 10 000 gated events were collected per treatment. Results were calculated using the Mod-fit program (Topsham, ME, USA).
TUNEL assay
Cells plated in 8-well chamber slides at 10 000 cells/well were incubated with drugs for 48 h, and formalin-fixed. FFPE tumors from mice were sectioned onto slides. Apoptotic cells were detected by TUNEL, using TACS TdT In Situ Apoptosis Detection Kit: DAB (R&D systems, Minneapolis, MN, USA), with hematoxylin counterstain. The number of TUNEL-positive cells was determined by counting four fields/treatment, and apoptosis was calculated as the number of apoptotic cells/total number of cells × 100.
BrdU incorporation
Cells plated at 5000 cells/well in 96-well plates were treated with drugs for 48 h. BrdU incorporation was determined by ELISA cell proliferation kit (Roche, Indianapolis, IN, USA) and absorbance was determined on a KC Junior Plate Reader. Experiments included six replicates per treatment, and were repeated at least twice. cGMP and cAMP analyses Cells plated at 100 000 cells/well in 24-well plates were treated for 60 min. Lysates were analyzed for cAMP or cGMP using respective colorimetric competitive ELISA kits (Cayman Chemical; cAMP: 581001, cGMP: 581021). Limits of detection were 0.3 pmol/ml (cAMP) and 0.23 pmol/ml (cGMP).
Animals
Eight-week-old female athymic nu/nu mice were obtained from the NCI. Mice were housed four/cage in sterile cages, kept under light/dark cycles (12 h:12 h), and were acclimated for 7-10 days before experiments. The protocol (#04-06-29-01) was approved by the University of Cincinnati Institutional Animal Care and Use Committee.
Mouse xenograft models MDA-MB-231 cells (1.5 × 10 6 cells/60 μl) or SUM159 cells (1 × 10 6 cells/60 μl) were suspended 1:1 in PBS/Matrigel and inoculated into the inguinal mammary fatpad or subcutaneously in the flank, respectively. Tumor dimensions were measured twice/week and tumor volume calculated as length × width 2 × 0.52. Power calculation, based on previous studies in our laboratory and those in the literature, predicts a 90% chance of finding significant differences (α = 0.05, power of 0.8) when using eight mice/ treatment. Mice that were killed due to health issues were excluded. Mice were randomized among treatments. When tumors were 200-250 mm 3 in volume, Alzet osmotic mini-pumps (model 1004, Durect Corporation, Cupertino, CA, USA) with a 100-μl reservoir, rated for a continuous delivery at 0.11 μl/h for 4 weeks, were implanted subcutaneously in the dorsal neck. The pumps delivered PBS (control), high Fen (400 ng/kg/min) or low Fen (133 ng/kg/min). After 3 weeks, animals were killed and tumors were weighed. Tumors were FFPE for TUNEL assay or histopathology. One group with SUM159-derived tumors had the pumps removed after 1 week and tumor monitoring continued for another 2 weeks.
In vivo fluorescence imaging
Rabbit anti-D1R mAb were fluorescently labeled using a SAIVI Alexa Fluor 647 Antibody Labeling Kit (Molecular Probes by Life Technologies). These antibodies (100 μg proteins) were injected via tail vein into mice with MDA-MB-231-derived inguinal tumors of moderate size. Mice were imaged 24 h after the injection, using Kodak Multispectral Imaging FX (Carestream Molecular Imaging). Rabbit IgGs labeled with Alexa Fluor 647 and injected into mice showed no specific fluorescence in the tumors.
Statistics
Number of replicates for each experiment with cultured cells was determined by the plate layout. Student's t-test or ANOVA was used where appropriate. P-values ⩽ 0.05 were considered as significant. All experiments were repeated at least three times, unless otherwise noted.
